GlycoMimetics, Inc. (GLYC)

Market Cap	110.21M
Revenue (ttm)	10,000
Net Income (ttm)	-36.90M
Shares Out	64.45M
EPS (ttm)	-0.58
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	546,113
Open	1.800
Previous Close	1.855
Day's Range	1.690 - 1.810
52-Week Range	1.110 - 3.530
Beta	2.19
Analysts	Strong Buy
Price Target	10.00 (+484.8%)
Earnings Date	May 6, 2024

About GLYC

GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protei...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 10, 2014
• Employees: 35
• Stock Exchange: NASDAQ
• Ticker Symbol: GLYC

Financial Performance

In 2023, GlycoMimetics's revenue was $10,000, a decrease of -86.67% compared to the previous year's $75,000. Losses were -$36.90 million, -20.97% less than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for GLYC stock is "Strong Buy." The 12-month stock price forecast is $10.0, which is an increase of 484.80% from the latest price.

Price Target

$10.0

(484.80% upside)

Analyst Consensus: Strong Buy